Not all of medicine is science. Some of it is an art.
In the space between unaffordable prescriptions and unmet need, a growing number of Americans have quietly become their own pharmacists — measuring, injecting, and adjusting doses of powerful weight-loss drugs without clinical guidance. The phenomenon of 'microdosing' GLP-1 medications like semaglutide reflects a deeper tension in modern medicine: when science produces transformative drugs but systems fail to deliver them equitably, patients improvise. Regulators and pharmaceutical companies are now moving to close the gaps that made this possible, even as the human stories behind the trend resist easy resolution.
- With brand-name weight-loss injections costing over $1,300 a month and insurance often refusing to cover them, patients are turning to compounded powders and self-administered syringes to access drugs their doctors won't prescribe.
- The DIY dosing movement has outpaced the science — there is no clinical data on how these drugs affect people with lower BMIs or what the long-term consequences of off-label microdosing might be.
- A small but vocal group of physicians is quietly supporting the practice, arguing that individual responses vary so widely that rigid dosing protocols may do more harm than good for certain patients.
- Pharmaceutical manufacturers are fighting back, pressuring the FDA to shut down compounding pharmacies and arguing that complex biologics cannot be safely replicated outside approved facilities.
- The FDA's own position is unstable — it reversed a crackdown on compounders after a legal challenge, leaving the regulatory future of DIY weight-loss drugs unresolved and the market in limbo.
Shauna Bookless never expected to become her own pharmacist. After her doctor deemed Wegovy medically unnecessary and insurance declined to cover it, she ordered compounded semaglutide online for $130 — white powder, sterile water, needles — and began injecting herself weekly at a fraction of the standard dose. Three months later, she had lost twenty-three pounds and was still experimenting with how low she could go.
Hers is not an isolated story. As GLP-1 drugs have surged in popularity — backed by research showing semaglutide reduces cardiovascular events by 20 percent and overall mortality by 19 percent — patients priced out of the market have turned to compounded versions and self-directed dosing. Wegovy runs $1,300 a month without insurance. Compounded alternatives cost a fraction of that. The practice has acquired a name borrowed from cosmetic culture: microdosing Ozempic.
The medical community is split. Some physicians, like Dr. Tasneen Bhatia in Los Angeles, estimate that 10 to 20 percent of their patients are microdosing, particularly those seeking modest weight loss or struggling with side effects. Dr. Suzanne Trott, a Beverly Hills surgeon, opened a microdosing clinic for patients who had reached their goal weight and wanted to maintain it. 'Not all of medicine is science,' she said. 'Some of it is an art.' Others are more cautious — not because clear risks have been identified, but because, as one USC endocrinologist put it, no one has been studying these patients in any rigorous way.
Novo Nordisk has asked the FDA to bar compounding pharmacies from replicating its drugs, arguing the formulations are too complex to copy safely. Regulators recently declared the Zepbound shortage over and signaled a crackdown — only to reverse course after a lawsuit from a compounding trade group. Semaglutide may be next in line for similar scrutiny. For now, clinics like Trott's are nearly full, running an experiment that exists entirely outside the clinical literature, and the question hanging over all of it is simply how long that will be allowed to continue.
Shauna Bookless mixed her first dose in a Hollywood kitchen, measuring out white powder and sterile water into a vial she'd ordered online for $130. She had never imagined becoming her own pharmacist, but after her doctor told her that Wegovy—a popular weight-loss injection—wasn't medically necessary for her and that insurance wouldn't cover it, she found herself on the fringes of a booming, largely unregulated market. The powder arrived two days later, along with needles. She began injecting herself weekly with semaglutide, the active ingredient in both Ozempic and Wegovy, but at a fraction of the recommended dose. Within three months, she had lost twenty-three pounds and was experimenting with how low she could go.
Bookless is far from alone. As demand for GLP-1 weight-loss drugs has exploded—driven by landmark research showing that semaglutide reduces cardiovascular events by 20 percent and lowers overall mortality by 19 percent—patients are taking dosing into their own hands. Some are microdosing, using smaller-than-recommended amounts to stretch supplies, cut costs, and potentially reduce side effects like nausea and constipation. The phenomenon has a name now, borrowed from the lexicon of cosmetic procedures: microdosing Ozempic, which sounds gentler than the reality of what's happening. Wegovy costs $1,300 a month without insurance. Med-spas charge around $1,000 monthly. Compounded versions from laboratories cost a fraction of that. For people like Bookless, a new therapist at the time, the math was simple.
The drugs themselves are remarkable. GLP-1 and GIP are naturally occurring hormones that regulate insulin, appetite, and metabolism. When the FDA approved Wegovy in 2021—the first new weight-loss drug in seven years—pharmaceutical companies began marketing them aggressively for weight management. The enthusiasm was justified by science: more than 70 percent of American adults are overweight or obese, conditions that increase risk for heart attack, stroke, and early death. But the popularity created shortages and sky-high prices, pushing some patients toward compounded versions made by pharmacies operating in a legal gray area. Federal law normally prohibits pharmacies from copying commercially available drugs, but when medications are in short supply, regulators don't consider them "commercially available," opening the door for compounders to operate legally—for now.
Doctors are divided. Dr. Vijaya Surampudi at UCLA's Medical Weight Management Clinic works with patients who prefer lower doses, emphasizing that responses vary widely and that higher doses don't necessarily correlate with how much weight someone needs to lose. Dr. Tasneen Bhatia, an integrative medicine physician in Los Angeles, estimates that 10 to 20 percent of her clients are microdosing, particularly those aiming to lose 20 pounds or less or those sensitive to side effects. She envisions a future where people use these drugs intermittently, cycling on and off as needed rather than taking them indefinitely. Dr. Suzanne Trott, a Beverly Hills plastic surgeon, started a microdosing clinic after patients reached their goal weight and wanted to maintain it. She works primarily with tirzepatide, the drug behind Zepbound, which she says has fewer side effects. "Not all of medicine is science," she said. "Some of it is an art."
But pharmaceutical companies and regulators are not convinced. Novo Nordisk, which makes Wegovy, issued a statement saying the company "does not condone these practices" and that only the marked doses on pens—0.25, 0.5, 1.0, and 2.0 milligrams—have been studied in clinical trials. The company has asked the FDA to bar compounding pharmacies from making copies of its drugs, arguing the medication is too complex for others to manufacture safely. Medical experts acknowledge a fundamental gap: there is no robust data on the effects of these drugs on people with lower BMIs or on the long-term consequences of off-label use. "We don't have any clearly identified risks," said Dr. Alyssa Dominguez, an endocrinologist at USC Keck School of Medicine, "but we don't know because we haven't been looking at those people in the scientific way."
The regulatory landscape is shifting. Last week, the FDA announced that the shortage of Eli Lilly's Zepbound had ended, and the company sent cease-and-desist letters to compounders. But after a lawsuit from a compounding trade group, the FDA reversed course and said it would allow pharmacists to continue making compounded versions while it reexamines the shortage. Semaglutide compounders could be next. As shortages ease and manufacturers press for restrictions, the DIY weight-loss drug market that has flourished in the gaps of supply and affordability may soon face a crackdown. For now, clinics like Trott's are nearly at capacity, with dozens of patients experimenting with doses and schedules that exist nowhere in the clinical literature. The question is how long regulators will allow this experiment to continue.
Notable Quotes
I'm playing doctor— Shauna Bookless, describing her DIY approach to weight-loss medication
We don't have any clearly identified risks of people using it if they don't meet criteria. But we don't know because we haven't been looking at those people in the scientific way.— Dr. Alyssa Dominguez, endocrinologist at USC Keck School of Medicine
The Hearth Conversation Another angle on the story
Why did Bookless go to such lengths instead of just waiting for her insurance to cover it?
Because the barrier wasn't time—it was the rule itself. Her BMI didn't meet the threshold. Insurance companies have drawn a line, and she fell on the wrong side of it. For someone who felt unhappy with her weight and had heard success stories from friends, that line felt arbitrary.
But isn't there real danger in someone dosing themselves without a doctor watching?
Yes, and that's what the experts keep saying. The problem is we don't actually know what the danger is. These drugs haven't been studied in people like Bookless—people with lower BMIs, people taking smaller doses. So when doctors say "we don't know," they mean it literally. There's no data.
So some doctors are okay with microdosing?
Some are. The ones who see patients every week, who can monitor how their body responds. They're saying that one-size-fits-all dosing doesn't make sense—that a person who needs to lose 20 pounds might not need the same dose as someone who needs to lose 100. That's not fringe thinking. That's medicine.
Why would Novo Nordisk care if people use less of their drug?
Because they can't control it, and because it undermines the market they've built. If people figure out they only need a quarter of the dose, the company sells a quarter as much. And if something goes wrong, they're liable. The compounders, though—they're operating in a legal shadow. That's harder to control.
Is this going to last?
Probably not. Once the shortages end, the FDA will likely crack down on compounders. Novo Nordisk is already pushing for it. The window where this was possible—where shortages made compounding legal and prices made it necessary—that window is closing. In a year, this story might look very different.